此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

基因阻滞对全膝关节置换术手术的功效

2026年10月14日 更新者:Mustafa Azizoğlu、Mersin University

术前施用术前施用的基因阻滞在总膝关节置换术上的术后镇痛功效:一项随机对照研究

This prospective, randomized, double-blind, placebo-controlled trial evaluated the analgesic efficacy of preoperative ultrasound-guided genicular nerve block (GNB) in patients undergoing total knee arthroplasty.

A total of 64 patients were randomly assigned to two groups (32 patients per group). The GNB group received 5 mL of 0.25% bupivacaine at each of three genicular nerve targets, whereas the placebo group received 5 mL of 0.9% normal saline at the same anatomical targets.

All patients underwent standardized general anesthesia and received postoperative multimodal analgesia, including intravenous patient-controlled morphine analgesia.

The primary outcome was movement-evoked pain intensity, assessed using the visual analog scale (VAS) at 24 hours postoperatively. Secondary outcomes included pain scores at other postoperative time points, opioid consumption, and knee range of motion.

Participants and outcome assessors were blinded to group allocation.

研究概览

详细说明

Patients scheduled for elective primary unilateral total knee arthroplasty were randomly allocated in a 1:1 ratio to the genicular nerve block (GNB) group or the placebo control group.

Approximately 30 minutes before surgery, all patients underwent an ultrasound-guided injection procedure targeting the superomedial, superolateral, and inferomedial genicular nerves.

Patients in the GNB group received 5 mL of 0.25% bupivacaine at each target (total volume: 15 mL). Patients in the placebo control group received 5 mL of 0.9% normal saline at each corresponding target (total volume: 15 mL).

The injections were performed by an anesthesiologist who was aware of group allocation and was not involved in postoperative outcome assessment. Participants and outcome assessors remained blinded to treatment allocation.

All patients received standardized general anesthesia and postoperative multimodal analgesia, including intravenous paracetamol, intramuscular diclofenac, and patient-controlled intravenous morphine analgesia.

Postoperative pain intensity was assessed using the visual analog scale (VAS) at rest and during movement. The primary outcome was movement-evoked VAS at 24 hours after surgery. Secondary outcomes included other postoperative VAS measurements, morphine consumption, and knee range of motion.

研究类型

介入性

注册 (实际的)

64

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Scheduled for unilateral and primary total knee arthroplasty
  • Older than 18 years of age

Exclusion Criteria:

  • Younger than 18 years
  • Bilateral knee arthroplasty
  • Revision case of knee arthroplasty

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Genicular block group

Patients received preoperative ultrasound-guided genicular nerve block with 5 mL of 0.25% bupivacaine injected at each of three anatomical targets: superomedial, superolateral, and inferomedial genicular nerves (total volume: 15 mL). All patients received standardized general anesthesia and postoperative multimodal analgesia, including intravenous patient-controlled morphine analgesia, paracetamol, and diclofenac.

Patients received preoperative ultrasound-guided genicular nerve block with 5 mL of 0.25% bupivacaine injected at each of three anatomical targets: superomedial, superolateral, and inferomedial genicular nerves (total volume: 15 mL).

Standardized postoperative multimodal analgesia consisting of intravenous paracetamol 1 g every 8 hours and intramuscular diclofenac sodium 75 mg every 12 hours during the first 48 postoperative hours, administered to both study groups.

Postoperative intravenous patient-controlled analgesia with morphine, programmed to deliver a 1 mg demand dose with a 15-minute lockout interval. The same PCA regimen was used in both study groups.

安慰剂比较:placebo

Patients received preoperative ultrasound-guided placebo injections consisting of 5 mL of 0.9% normal saline at each of the same three genicular nerve targets (total volume: 15 mL). All patients received standardized general anesthesia and postoperative multimodal analgesia, including intravenous patient-controlled morphine analgesia, paracetamol, and diclofenac.

Standardized postoperative multimodal analgesia consisting of intravenous paracetamol 1 g every 8 hours and intramuscular diclofenac sodium 75 mg every 12 hours during the first 48 postoperative hours, administered to both study groups.

Postoperative intravenous patient-controlled analgesia with morphine, programmed to deliver a 1 mg demand dose with a 15-minute lockout interval. The same PCA regimen was used in both study groups.

Patients received preoperative ultrasound-guided placebo injections consisting of 5 mL of 0.9% normal saline at each of the same three genicular nerve targets (total volume: 15 mL).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Visual Analog Scale Measure
大体时间:0-48 hours

VAS scores are assessed at 0th, 24th and 48th hours post operatively VAS score consists of 0-10 in numbers, the bigger the number the worse the pain

0-48 hours

次要结果测量

结果测量
措施说明
大体时间
opioid consumption
大体时间:0-48 hours

Morphine consumption is assesed by PCA

0-48 hours
Range of Motion Measurements
大体时间:0-48 hours

Knee range of motion (ROM) are assessed in degrees during active knee flexion. Measurements are obtained preoperatively and at predefined postoperative time points. Higher values indicate greater knee flexion.

0-48 hours

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Mustafa Azizoglu, Associated Professor、Mersin university Faculty of Medicine, Department of Anesthesiology and Reanimation

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年5月15日

初级完成 (实际的)

2026年3月30日

研究完成 (实际的)

2026年5月15日

研究注册日期

首次提交

2025年4月17日

首先提交符合 QC 标准的

2025年4月17日

首次发布 (实际的)

2025年4月24日

研究记录更新

最后更新发布 (实际的)

2026年10月19日

上次提交的符合 QC 标准的更新

2026年10月14日

最后验证

2026年10月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅